This study is a placebo-controlled study to assess the safety and tolerability of a novel
antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight
days. Assessments include blood sampling to determine drug concentrations, psychiatric
assessments while under treatment, and movement assessments to evaluate potential side
effects.